Cymbalta(R) Significantly Reduced Osteoarthritis Knee Pain in...(oducts byapplying the latest research fr...),Health

Date:1/30/2009

oducts by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers -- through medicines and information -- for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

P-LLY

This press release contains forward-looking statements about the potential of Cymbalta for chronic pain including the management of osteoarthritis pain of the knee and reflects Lilly's current beliefs. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. There is no guarantee that the product will continue to be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's filings with the United States Securities and Exchange Commission. Lilly undertakes no duty to update forward-looking statements.

    P-LLY

(1) Chappell, A, et al. Duloxetine 60 to 120 mg Once Daily Versus Placebo in the Treatment of Patients with Osteoarthritis Knee Pain. Poster presented at the American Academy of Pain Medicine Annual Meeting. 29 January 2009.

(2) Lawrence, RC, et al. Estimates of the Prevalence of Arthritis and Other Rheumatic Conditions in the United States. 2008. Arthritis and Rheumatism (58):26-35.

(3) National Pain Foundation Web site - http://www.nationalpainfoundation.org/MyTreatment/articles/Arthritis_Types.asp , accessed on 22 December 2008.

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO )

'/>"/>

SOURCE Eli Lilly and Company Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related medicine technology :

1. Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain
2. Patients Taking Cymbalta(R) Reported Reduced Pain Severity of Osteoarthritis of the Knee in New Study
3. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration
4. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
5. New Data Suggest Cymbalta(R) Reduced Pain in Fibromyalgia Patients With and Without Depression
6. AMT: Glybera(R) Lowers Pancreatitis Incidence Significantly
7. Retigabine Significantly Reduces the Number of Seizures in Adults With Inadequately Controlled Partial-Onset Epilepsy
8. Phase III Trial Results Show Elitek(R) (rasburicase) Significantly Reduced Plasma Uric Acid Levels versus Allopurinol in Adults with Hematologic Cancers at Risk for Tumor Lysis Syndrome
9. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
10. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
11. Study Suggests Treatment with Paliperidone ER Significantly Improves Symptoms of Schizoaffective Disorder